-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
February 2021
-
Mary Jo Fidler, MD
Mary Jo Fidler, MD, is now Section Chief for Section of Medical Oncology at Rush Medical College. She has been on staff in medical oncology at RUSH since 2007. Dr. Fidler is a member of both the Communications Committee and ILCN Editorial Group.
-
Premonitions About Lung Cancer for the Next Decade
Daniel Kahneman, PhD, was awarded the Nobel Prize in 2002 for proving, among other things, that intuitions—even expert ones—fail and that formulas based on data fare better. Intuitions are more reliable for short-term predictions if they are based on stable environments.1 For decades, we have had a relatively stable environment in the prevention, diagnosis, and…
-
Pyrotinib: A Potential New Anti-HER2 Therapy for Lung Cancer
HER2 can be aberrantly expressed in NSCLC, caused by its mutation and/or amplification.1 Like in breast cancer, patients with NSCLC with somatic HER2 mutations rarely show concurrent gene amplification, highlighting mutation as an independent factor.2 However, previous clinical trials with HER2-targeted agents have yielded disappointing results in HER2-mutant NSCLC. Although only accounting for a minority…
-
Tepotinib Approved for MET Exon 14 Skipping Mutated Metastatic NSCLC
February 3, 2021—Tepotinib was approved for treatment of patients with metastatic NSCLC who harbor MET exon 14 skipping alterations. Approval was based on data from the VISION trial (NCT02864992). VISION, a multicenter, nonrandomized, open-label, multicohort trial, enrolled 152 patients with advanced or metastatic NSCLC and MET exon 14 skipping alterations. Patients received 450 mg of…
-
IASLC GENERAL DISCLAIMER
All information and materials presented on or through IASLC’s websites, or made available or provided by or on behalf of IASLC during any webinar, seminar, or other event or activity, is made available solely for general information purposes. IASLC does not warrant the accuracy, completeness, or usefulness of this information. Without limiting the foregoing, such…
-
Acute Admissions Rates for Lung Cancer Patients Up During Pandemic, Not Linked to COVID-19
Data from a single-center study in Scotland suggested that there were more patients with lung cancer admitted acutely with cancer, non-COVID-19-related illness during the COVID-19 pandemic. “Early and late lockdown were characterized by a reduction in self-presentation and longer resulting admission suggesting that patients were admitted with more complex pathology and consequently had longer admission,”…
-
Modeling Analyses Show That Expansions in Lung Cancer Screening Guidelines to Better Capture Underrepresented Populations Still Need Work
Two abstracts presented at the 2020 World Conference on Lung Cancer shed light on how changes in current screening guidelines can influence lung cancer detection rates, specifically among underrepresented populations. As both studies illustrate, sometimes seemingly innocuous changes intended to improve detection rates can actually have negative consequences. Performance of the Draft 2020 USPSTF Lung…
-
Young Investigators Awarded Grants to Study COVID-19 and Lung Cancer
Lung Ambition Alliance to award four new Junior Faculty Research Grants. Four early-career researchers have been selected to receive the Lung Ambition Alliance Junior Faculty Grants for the Study of COVID-19 and Lung Cancer. Research shows that patients with lung cancer have worse outcomes with COVID-19 and these grants are intended to fund groundbreaking research…
-
Lung Ambition Alliance: Stronger Together
The IASLC has formed an alliance with the Global Lung Cancer Coalition (GLCC), Guardant Health, and AstraZeneca to accelerate the pace of lung cancer survival worldwide. This collaborative effort—known as the Lung Ambition Alliance—allows scientists, specialists, advocates, and patients to break the barriers limiting progress with a goal to double 5-year survival rates of lung…
-
Use of Predictive Biomarkers, Incorporating Chemotherapy—What Is Best When Using Immunotherapy in Advanced NSCLC?
Oncologists currently have three main therapeutic strategies to choose from when managing patients with advanced NSCLC who lack targetable mutations: immunotherapy alone, immunotherapy-immunotherapy combinations, or immunotherapy-chemotherapy combinations. So how does one choose between them, and should we be selecting patients for therapy? These questions were addressed during an Education Session entitled, “Pro-Con: Do We Need…